Valur Ragnarsson, CEO of Medis, recently made the following announcement to our customers regarding the recent deal:
On 17 January 2014, Aurobindo Pharma Limited made a binding offer to acquire the generics commercial operations of the global pharmaceutical company Actavis plc in seven countries in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes.
Under the terms of the agreement, Aurobindo would acquire Actavis’ pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products and marketing authorisations. Production sites, including our cytostatic site in Nerviano Italy, are not included in the transaction.
While a binding offer has been made, this process is not yet complete.
If and when this transaction closes, we remain as committed as before to our customers. The announced transaction will therefore only foster the relationship between our customers and Medis as a supplier. Our commitment to our customers remains unchanged and they should expect no changes in their interaction with our teams.
You can read more about the deal on the Actavis website.